Clinical Features and Risk Factors of ICU Admission for COVID-19 Patients with Diabetes
Table 2
Treatments and outcomes of COVID-19 patients with non-DM or DM.
Total ()
Non-DM ()
DM ()
values
Treatments
Antiviral
233 (80.9%)
215 (81.4%)
18 (75%)
0.442
Antibiotics
244 (84.7%)
223 (84.5%)
21 (87.5%)
0.693
Vasoactive drugs
5 (1.7%)
4 (1.5%)
1 (4.2%)
0.341
Glucocorticoid
21 (7.3%)
19 (7.2%)
2 (8.3%)
0.838
Oxygen inhalation
None
88 (30.6%)
82 (31.1%)
6 (25.0%)
0.537
Normal-flux
184 (63.9%)
168 (63.6%)
16 (66.7%)
0.767
High-flux
16 (5.6%)
14 (5.3%)
2 (8.3%)
0.535
Tracheal intubation
8 (2.8%)
6 (2.3%)
2 (8.3%)
0.084
CPAP
32 (11.1%)
28 (10.6%)
4 (16.7%)
0.366
CRRT
5 (1.7%)
4 (1.5%)
1 (4.2%)
0.341
ECMO
4 (1.4%)
3 (1.1%)
1 (4.2%)
0.225
Glycemic control therapy
Use of insulin
NA
NA
6 (25%)
NA
Oral glucose control agents
NA
NA
15 (62.5%)
NA
Combined
NA
NA
3 (12.5%)
NA
Outcomes
Admission to ICU
27 (9.4%)
22 (8.3%)
5 (20.8%)
0.044
ARDS
3 (1.0%)
2 (0.8%)
1 (4.2%)
0.115
Clinical typesa (severe/critically severe)
30 (10.4%)
25 (9.5%)
5 (20.8%)
0.048
Data are presented as median (interquartile range) or number (percent). Abbreviations: NA: not applicable; CPAP: continuous positive airway pressure ventilation; CRRT: continuous renal replacement therapy; ECMO: extracorporeal membrane oxygenation; ICU: intensive care unit; ARDS: Acute Respiratory Distress Syndrome. aClinical types (severe/critically severe) were based on the notice on the issuance of a program for the diagnosis and treatment of novel coronavirus- (2019-nCoV-) infected pneumonia (7th edition) published by the General Office of National Health Committee.
